Which statement made by a client taking risperidone indicates the need for follow-up?

When a client states that they will need to have weekly tests to monitor their white blood cells while taking risperidone, it indicates a need for follow-up. This is primarily because risperidone can cause agranulocytosis, a potentially serious side effect that involves a dangerously low level of white blood cells. Regular monitoring is necessary in certain cases, especially for patients receiving high doses or those who have specific risk factors.

However, the statement about needing weekly tests suggests that the client may have a misunderstanding about their treatment plan or the necessity of such monitoring. Typically, routine blood tests for white blood cell counts are not a common practice for all patients on risperidone, thus prompting a need for clarification and follow-up from the healthcare provider to ensure the client understands their health management concerning this medication.

The other statements reflect appropriate monitoring or actions related to risperidone, such as reporting abnormal movements that could indicate extrapyramidal symptoms, notifying a physician of muscle stiffness, and managing dry mouth, which are all reasonable expectations for someone being treated with this antipsychotic medication.